A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 26 Mar 2018
At a glance
- Drugs AZD-1775 (Primary) ; Irinotecan (Primary)
- Indications Medulloblastoma; Neuroblastoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 07 Nov 2017 Planned number of patients changed from 128 to 154.
- 23 Oct 2017 Planned primary completion date changed from 31 Oct 2017 to 30 Apr 2021.
- 10 Jun 2017 Biomarkers information updated